CA
NZ
UK
AU
IND
US
Repligen (NASDAQ:RGEN) shares are sliding sharply, underperforming both the healthcare sector and the broader market, as growth concerns resurface following last week's second-quarter 2026 report, despite the company beating adjusted earnings and revenue estimates and raising full-year guidance.
Surgery Partners (NASDAQ:SGRY) shares traded higher amid ongoing consolidation and M&A activity across the physician-owned hospital and ambulatory surgery sector, highlighted by a rival's completed $3.9 billion take-private deal. That transaction has fueled investor speculation about valuation support and potential strategic interest in outpatient …
Alumis (NASDAQ:ALMS) shares plunged in active trading after the company announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary and secondary endpoints in the overall trial population. The trial enrolled 408 patients who received …
Arcturus Therapeutics (NASDAQ:ARCT) shares traded sharply higher after the company announced it will participate in five major investor conferences throughout September 2026, a flurry of institutional engagement that traders interpreted as a signal of management's confidence in near-term pipeline progress. The announcement comes as …
BillionToOne (NASDAQ:BLLN) shares traded higher after the company announced the launch of Northstar Origin, a new liquid biopsy add-on test that predicts tissue of origin directly from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnoses. The test is …
Climb Bio (NASDAQ:CLYM) shares are rallying sharply, outperforming the broader biotech sector, as investors continue to digest strong second-quarter 2026 results reported earlier in August, which showed a narrower-than-expected loss and highlighted pipeline progress across the company's lead programs.
Enovis (NYSE:ENOV) shares fell sharply after the company announced a binding offer to acquire eCential Robotics, a developer of surgical robotics and navigation technology, for an upfront enterprise value of €155 million plus up to €35 million in contingent milestone payments. Investors appear focused …
Erasca (NASDAQ:ERAS) shares are declining amid continued investor caution following the fallout from an April safety disclosure that revealed a treatment-related death in a clinical trial of the company's lead candidate, alongside a separate patent-infringement dispute that has weighed on sentiment toward the company's …
GMR Solutions (NYSE:GMRS) shares traded sharply higher, outperforming the broader healthcare sector, as investors continued to react to a wave of bullish analyst coverage following the company's second-quarter earnings. One research firm initiated or maintained a Buy rating with a $16 price target, adding …
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) finalized a super-priority DIP credit facility totaling as much as $77.25 million following its Chapter 11 filing, consisting of $19 million in fresh capital and $58.25 million in roll-up loans.
Please wait processing your request...